Polysilsesquioxane Nanoparticles for Triggered Release of Cisplatin and Effective Cancer Chemoradiotherapy

An innovative strategy is to utilize nanoparticle (NP)chemotherapeutics in chemoradiation. Since the most commonly utilized chemotherapeutic with   radiotherapy is   cisplatin,  the  development  of a NP cisplatin for chemoradiotherapy has the  highest  potential  impact  on this treatment. Here,  we report the development of a NP comprised of polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin prodrug (Cisplatin-PSQ) and its utilization in chemoradiotherapy using non-small cell lung cancer as a disease model.   Cisplatin-PSQ NP  has an  exceptionally high  loading of cisplatin. Cisplatin-PSQ NPs were        evaluated  in  chemoradiotherapy  in vitro and  in vivo.  They demonstrated significantly higher therapeutic  efficacy    when    compared to   cisplatin. These results suggest that the Cisplatin-PSQ NP holds potential for clinical translation in chemoradiotherapy.

Polysilsesquioxane Nanoparticles for Triggered Release of Cisplatin and Effective Cancer Chemoradiotherapy